In a first-of-its-kind study, research from the University of Vermont Cancer Center has linked phthalates, commonly called the “everywhere chemical,” to higher incidence of specific childhood cancers.

In recent years, total neoadjuvant treatment—a potent new therapy for advanced colorectal cancer—has emerged as the standard of care. But the treatment can be harsh, impacting quality of life for many patients. A new study published in Clinical Colorectal Cancer by a team of researchers affiliated with the University of Vermont Cancer Center highlights a variety of new colorectal cancer treatments that take into account both a patient’s likely health outcome and quality of life factors.

Frances Carr, Ph.D., professor of pharmacology at the Larner College of Medicine at the University of Vermont and UVM Cancer Center member, has been elected to the American Association for the Advancement of Science Fellows Class of 2021.

UVM Cancer Center researchers contributed to the establishment of a breast pre-cancer atlas, which establishes the molecular and cellular properties of early-stage breast cancer and is the result of a six-year, National Cancer Institute-funded, collaborative initiative.

The UVM Cancer Center Summer Student Fellowships in Cancer Research provide $3,000 stipends to graduate and medical students for cancer-related research projects, overseen by senior faculty members affiliated with the center.

In a ceremony held January 12, 2021, an outstanding early career physician-scientist in the University of Vermont’s Larner College of Medicine, Diego Adrianzen Herrera, M.D., was invested as the inaugural holder of the Early Career Green and Gold Professor of Medicine.

New research from U.S. Breast Cancer Surveillance Consortium (BCSC) members, including several University of Vermont researchers, found that from March to September 2020, breast biopsies and detected cancers at U.S. BCSC facilities dropped sharply, compared with the same span a year earlier.

With $3 million in support from a longtime major supporter of the University of Vermont Cancer Center, Randall F. Holcombe, M.D., M.B.A., was invested as the inaugural J. Walter Juckett Chair in Cancer Research in the Larner College of Medicine on November 3.

Linked to occupational asbestos exposure, malignant mesothelioma (MM) is an aggressive cancer arising primarily from the outer lining of the lungs with a dismal five-year survival rate of only five to 10 percent. Since 2004, only two therapies have been approved for the treatment of MM, which affects about 3,000 people a year in the United States. Now a promising new therapy for mesothelioma and metastatic cancer, arising from laboratory investigations at the University of Vermont, is about to enter a Phase I clinical trial.

Two members of the Larner College of Medicine community--Nick Lemon, information systems technical support staff member, and Katherine Strotmeyer, communications and community outreach director for the University of Vermont Cancer Center--were among the UVM stafff members who received a 2021 Our Common Ground award.

The University of Vermont Cancer Center hosted the 24th annual Women’s Health and Cancer Conference on October 1 from 7:30 a.m. to 2:30 p.m. The virtual event, which was free and open to the public, was sponsored by the Victoria Buffum Fund with an aim to empower and support individuals and communities with knowledge about cancer prevention, detection, treatment, and survivorship.

The National Cancer Institute (NCI) has awarded Noah Kolb, M.D., associate professor of neurological sciences at the University of Vermont's Larner College Medicine, and a team of researchers a $7 million grant to a develop a new intervention for chemo-induced neuropathy, one that can be as easily implemented in rural areas as large urban centers.

The FDA has revised the Emergency Use Authorizations (EUA) for both Pfizer and Moderna to authorize the use of a 3rd dose of COVID vaccine in the setting of immune compromised patients